✦ LIBER ✦

Pharmacokinetics of anastrozole and tamoxifen alone and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial

✍ Scribed by Trialists' Group, T.A.

Book ID: 119981116
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 77 KB
Volume: 85
Category: Article
ISSN: 0007-0920
DOI: 10.1054/bjoc.2001.1925

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 150 KB

3–38 Quality of Life of Postmenopausal W

3–38 Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

✍ Vassilopoulou-Sellin, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Assessing the quality of life of postmen

Assessing the quality of life of postmenopausal women randomized into the ATAC (“arimidex”, tamoxifen, alone or in combination) adjuvant breast cancer trial

✍ L. Fallowfield; D. Cella 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 223 KB

The ATAC (Arimidex™, Tamoxifen, Alone or

The ATAC (Arimidex™, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment

✍ Mike Baum 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Anastrozole is safer and may be more eff

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802–10

✍ Hetty Carraway; Antonio C. Wolff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB